US Private Payers Could Build Evidence On Alzheimer’s Drugs With Outcomes-Based Contracts
Executive Summary
Value-based contracting advocate Michael Sherman suggests creating an ‘enormous risk-based agreement as an industry’ between commercial payers and manufacturers of Alzheimer’s drugs that would condition reimbursement on achieving certain clinical endpoints.
You may also be interested in...
Amylyx ALS Drug May Drive Medicare Part D Redesign Efforts Based On Cost Sharing Concerns
Medicare could be an important payer for the eagerly awaited drug because the program covers ALS treatments for patients under 65 as well as older ones. Meanwhile, a draft Institute for Clinical and Economic Review raises questions about the drug's cost effectiveness.
Medicare Coverage Restrictions For Expensive Drugs: Did Aduhelm Let The Genie Out Of The Bottle?
Payer discomfort with accelerated approvals exploded into the public arena with the Medicare national coverage determination on Aduhelm and similar drugs, and developers worry that the fallout will be far reaching.
Medicare Coverage Restrictions For Expensive Drugs: Did Aduhelm Let The Genie Out Of The Bottle?
Payer discomfort with accelerated approvals exploded into the public arena with the Medicare national coverage determination on Aduhelm and similar drugs, and developers worry that the fallout will be far reaching.